MD Anderson Cancer Center — Clinical Trial Site

170 Registered trials

71 Currently recruiting

Organisation

MD Anderson Cancer Center

Location

Madrid, Spain

Identifier

ORG-100043950

Address

Calle De Arturo Soria Nº 270, 28033, Spain

Departments

-
#7004: Hematología
#93158011: Oncología
#98358011: Oncology
1308: Hematología y Oncología
172408: Hematología
201: Oncología
724001: Oncología
724002:Oncología
724004: Oncología
804: Ensayos Clínicos, Planta 1ª
Breast Cancer Unit
Cancer Center
Cirugía
Department of Oncology
ES011A: Oncología
Haematology
Hematologia
Hematology
Hematology Department
Jefe de Servicio de Hematologia y Hemoterapia
Medical Oncology
Medical Oncology Department
N/A
Onco-Hematology
Oncología
Oncología Médica
oncologia-hematologia
Oncology
Oncology Department
Oncology Physician
Oncology Service
Radiation Oncology
Research Facility
Servicio de Hematología
Servicio de Oncologia
Servicio de Oncología Medica
Unidad de ensayos clínicos
Unidad de Ensayos Clínicos-Oncología
Urology

Clinical trials at this site (170)

Search interface

A study to test the safety and effects of IOMX-0675, an antibody treatment, alone or with pembrolizumab, in patients with advanced or spread… Pending

2024-517449-14-00 Advanced/metastatic solid tumors 1
Atezolizumab, Pertuzumab and Trastuzumab with chemotherapy as neoadjuvant treatment of HER2 positive early high-risk and locally advanced br… Pending

2024-518026-32-00 Invasive Breast Cancer 5
Study to assess the efficacy and safety of Rina-S plus standard of care compared to standard of care for maintenance treatment of participan… Pending

2025-522167-15-00 Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC) 5
A Phase 1/2 Study of Inhaled KB707 in Patients Pending

2025-522723-98-00 solid tumor 9
A Study to Test How Well ZL-1310 may Work Compared to Therapies Selected by the Investigator in Treating Patients with Relapsed Small Cell L… Pending

2025-522818-23-00 Small Cell Lung Cancer (SCLC) 5
A Study of Vepugratinib (LY3866288) in Participants with Cancer in the Urinary Tract ( FORAGER-2 ) Pending

2025-522855-25-00 Urinary Bladder Neoplasms 5
A phase 3 study of orelabrutinib in combination with rituximab plus bendamustine (BR) compared with BR in subjects with treatment-naїve mant… Pending

2025-524241-27-00 Treatment-naїve mantle cell lymphoma (MCL) 5
Phase 3 Study of Revumenib in Combination with Intensive Chemotherapy in Newly Diagnosed NPM1-mutated AML Recruiting

2025-522279-27-00 Newly Diagnosed AML with an NPM1 mutation 5 2026-04-02
Studies testing Ziftomenib together with standard treatments in adults with newly diagnosed acute myeloid leukemia (AML) that has specific g… Recruiting

2025-521314-25-00 NPM1-m and KMT2A-r Acute Myeloid Leukemia 5 2026-03-19
PHASE II STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CAMIZESTRANT PLUS RIBOCICLIB IN PATIENTS WITH HORMONE RECEPTOR-POSITIVE (HR+) BREAST C… Recruiting

2024-520027-88-00 Patients with hormone receptor-positive (HR+) breast ca 4 2026-02-12
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III me… Recruiting

2025-521919-39-00 Resected stage IIB, IIC, or III melanoma requiring adju 3 2026-02-10
A multicenter, open-label, Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer Recruiting

2025-521277-14-00 Non-muscle invasive bladder cancer (NMIBC) 4 2025-12-09
A study comparing nadofaragene firadenovec with standard of care in adults with an increased risk that non-muscle invasive bladder cancer ma… Recruiting

2024-512029-10-00 Intermediate risk, non-muscle invasive bladder cancer 5 2025-12-05
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A phase 2 placebo-controlled trial to investigate visugromab and nivolumab with or without docetaxel in second-line treatment of participant… Recruiting

2024-516794-70-00 Metastatic non-squamous non-small cell lung cancer 4 2025-11-03
A study to compare pharmacokinetics, efficacy, safety, and immunogenicity of MB12 (proposed pembrolizumab biosimilar) to Keytruda® in non-sm… Recruiting

2024-515853-48-00 advanced/metastatic non-squamous non-small cell lung ca 5 2025-09-05
A phase 2 placebo-controlled trial to investigate visugromab in combination with immunochemotherapy (ICT) in first-line treatment of partici… Recruiting

2024-516792-32-01 Metastatic non-squamous non-small cell lung cancer 4 2025-07-18
A phase 2/3, multi-center, study of L-Annamycin in combination with cytarabine vs. placebo in combination with cytarabine as second line the… Recruiting

2024-518359-47-00 Acute Myeloid Leukemia 10 2025-06-17
First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Recruiting

2023-506842-22-00 Recurrent endometrial cancer, recurrent epithelial ovar 7 2025-05-19
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting

2023-507936-20-00 Acute myeloid leukemia 5 2025-05-05
A Study to Assess Livmoniplimab in Combination with Budigalimab Versus Chemotherapy in Adult Participants with Metastatic Urothelial Carcino… Recruiting

2024-515506-11-00 Urothelial Carcinoma 4 2025-03-24
A Phase 1, dose determining study of EXS73565 in participants with relapsed or refractory B‑cell malignancies. Recruiting

2024-516869-36-00 Relapsed or refractory B-cell malignancies: chronic lym 1 2025-02-17